Obesity-specific improvement of lung cancer outcomes and immunotherapy efficacy with metformin
Metformin may improve lung cancer-specific clinical outcomes in obese and overweight lung cancer patients and enhance immunotherapy efficacy in this growing population. This work identifies obesity as a potential predictive biomarker of metformin's anticancer and immunotherapy-enhancing properties in lung cancer while shedding light on the underlying immunological phenomena.
Authors
- Garrison Shaller
- Cara Petrucci
- Eric Kannisto
- Spencer R. Rosario (ORCID: https://orcid.org/0000-0002-2626-9257)
- Randall J. Smith (ORCID: https://orcid.org/0000-0001-8114-3086)
- Stephanie N. Sass
- Sawyer Bawek (ORCID: https://orcid.org/0000-0002-0284-5547)
- Aravind Srinivasan (ORCID: https://orcid.org/0000-0002-4424-474X)
- Yeshwanth Vedire (ORCID: https://orcid.org/0000-0003-3611-2592)
- Sukumar Kalvapudi (ORCID: https://orcid.org/0000-0003-0233-4648)
- Robert Zollo (ORCID: https://orcid.org/0000-0001-5415-4855)
- Deschana Washington
- Prantesh Jain (ORCID: https://orcid.org/0000-0003-2771-4612)
- Sai Yendamuri (ORCID: https://orcid.org/0000-0001-6654-3487)
- Akhil Goud Pachimatla (ORCID: https://orcid.org/0000-0002-0276-6769)
- Joseph Barbi (ORCID: https://orcid.org/0000-0002-5632-0885)
- Vethanayagam Rr
Institutions
- Roswell Park Comprehensive Cancer Center (US)
- University at Buffalo, State University of New York (US)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1093/jnci/djae295
- Citations
- 8
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.87
Funders
- Roswell Park Cancer Institute
- University at Buffalo
- National Cancer Institute